Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Natural killer cells complexed with a bispecific antibody may provide new...

Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston...

Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma ( Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA )

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...

$Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )$

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

Immune gene signatures for predicting response to neoadjuvant...

Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda...

Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC ( Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )

ASCO GU 2022: Latest in mHSPC

Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith

ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma...

Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The...

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis ( Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Netherlands )

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible...

Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Update on the new EUSOMA quality indicators for breast cancer

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

Lung cancer in India

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India

Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )

More from ecancer